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Profile of veliparib and its potential in the 
treatment of solid tumors
Lars M wagner
Division of Pediatric Hematology/
Oncology, University of Kentucky, 
Lexington, KY, USA
Abstract: Inhibition of poly(ADP-ribose) polymerase (PARP) is an attractive therapeutic 
strategy because of the importance of this pathway in restoring DNA damage. Small-molecule 
inhibitors of PARP appear most effective when used to treat tumors with underlying defects 
in DNA repair, or when combined with DNA-damaging agents. Veliparib is one of several 
recently developed oral inhibitors of PARP currently in clinical trials. This review summarizes 
the pharmacology, mechanisms of action, toxicity, and activity of veliparib seen in clinical 
trials to date. Also discussed are proposed mechanisms of resistance, potential biomarkers of 
activity, and issues regarding patient selection and combination therapies that may optimize 
use of this exciting new agent.
Keywords: veliparib, solid tumors, PARP inhibitor, BRCA
Introduction
The poly(ADP-ribose) polymerase (PARP) family of proteins consists of over 15 
different enzymes, which engage in a variety of cellular functions, including cell 
cycle regulation, transcription, and repair of DNA damage.1 PARP-1 is the most 
abundant and best characterized protein in this group and is critical to the repair 
of single-strand DNA breaks through the base excision repair pathway. Effective 
inhibition of PARP-1 leads to the accumulation of single-strand breaks, which 
ultimately results in double-strand breaks. Usually such double-strand breaks are 
repaired by homologous recombination (HR), but in cells with defective HR, PARP 
inhibition can result in chromosomal instability, cell cycle arrest, and subsequent 
apoptosis.
The inability of HR to correct double-stranded breaks has been observed in tumors 
with mutations in the breast cancer-related genes BRCA1 and BRCA2, which code for 
proteins essential for normal HR function. The use of small-molecule PARP inhibitors 
to exploit this genetic vulnerability in DNA damage repair is an example of synthetic 
lethality, in which the simultaneous inhibition of two pathways leads to cell death, 
whereas blocking either pathway alone is not lethal. Encouraging preclinical results 
for PARP inhibitors in the treatment of BRCA-mutated tumor cells provided strong 
rationale for the clinical testing of these agents in patient populations most likely to 
carry these mutations, such as those with breast or ovarian cancer. This therapeutic 
strategy has now been validated by the recent US Food and Drug Administration 
(FDA)-accelerated approval for the PARP inhibitor olaparib as monotherapy to treat 
patients with BRCA-mutated advanced ovarian cancer who have been treated with 
three prior lines of chemotherapy.2
This review highlights the development of another PARP inhibitor, veliparib 
(ABT-888; AbbVie Pharmaceuticals, Chicago, IL, USA). Concepts general to all 
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PARP inhibitors are discussed, with specific attention to how 
veliparib is being developed in clinical trials.
Biochemistry and pharmacology 
of veliparib
The complete chemical name of veliparib is 2-[(R)-2-
methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide, 
and the chemical structure is shown in Figure 1. Veliparib is 
able to potently inhibit both PARP-1 and PARP-2, with K
i
s 
(inhibitory constants) of 5.2 and 2.9 nmol/L, respectively.3 
As seen with many PARP inhibitors, this activity is generally 
selective, and veliparib does not appear to have substantial 
effects on other receptors or ion channels at pharmacologi-
cally relevant concentrations.
In a 2009 Phase 0 clinical trial of veliparib in adults with 
advanced cancers, patients received single oral doses of 10, 
25, or 50 mg veliparib.4 Veliparib showed good oral bioavail-
ability, with peak absorption between 0.5 and 1.5 hours, and 
a maximum concentration of 0.45 µM after a single dose of 
50 mg. Significant inhibition of PARP levels in both tumor 
tissue and peripheral blood mononuclear cells was observed 
3–6 hours after administration, with recovery at 24 hours 
in both preclinical models and patients. These findings led 
to the recommendation of twice-daily (bid) administration, 
in order to ensure adequate PARP inhibition over longer 
periods of time.
Population modeling from 325 adult patients receiving 
veliparib bid in one of four clinical trials showed that this 
drug’s pharmacokinetics are best described with a one-
compartment model with first-order absorption and elimi-
nation.5 Veliparib is predominantly eliminated in the urine 
as the unchanged parent drug. This process is facilitated by 
drug uptake via the organic cation transporter OCT2 into 
the renal tubule. Although mostly eliminated by renal clear-
ance, an estimated 13% of veliparib also undergoes hepatic 
metabolism by CYP2D6,6 producing the lactam metabolite 
M8, which is a much weaker PARP inhibitor than the parent 
compound.7
Dose adjustments of veliparib on the basis of body size, 
sex, age, ethnicity, or liver function do not appear routinely 
necessary. However, creatinine clearance can affect veliparib 
exposures, and modifications should be considered in patients 
with impaired renal function. Patients who have certain 
CYP2D6 polymorphisms, or who are receiving coadminis-
tration of OCT2 inhibitors such as cimetidine, may also be 
at risk for poor clearance and a clinically relevant increase 
in veliparib exposure.8 However, it is felt that veliparib 
has a generally low likelihood for meaningful drug–drug 
interactions.9
Mechanisms of action
A comprehensive understanding of the possible mechanisms 
of action of PARP inhibitors helps provide rationale for 
patient selection and study design. BRCA-mutated tumors are 
well established to have inadequate DNA repair machinery, 
and so be sensitive to PARP inhibition through the concept of 
synthetic lethality. Importantly, HR deficiencies can also be 
seen in other contexts as well, including tumors with defects 
in the DNA damage sensors ATM (ataxia-telangiectasia 
mutated) and ATR (ATM- and RAD3-related protein),10 
PTEN mutations,11 or defects in the Fanconi repair pathway.12 
This information has been used to expand the rationale for 
treatment to include tumors that may have limited capacity 
for DNA repair (also termed “BRCAness”) that could predict 
the activity of PARP inhibitors.
The genetic knockout of PARP-1 substantially impairs 
DNA repair following damage from radiation or cytotoxic 
chemotherapy agents;13 accordingly, investigators have 
combined PARP inhibitors with conventional cancer treat-
ments known to damage DNA. As will be discussed, this 
approach has been or is being investigated with therapeutic 
irradiation as well as a wide variety of cytotoxic agents, 
including temozolomide, cisplatin, carboplatin, doxorubicin, 
paclitaxel, and topotecan.
In addition to these mechanisms of action, PARP inhibi-
tors may also poison DNA by stabilizing PARP-1 and 2 at 
sites of DNA damage, generating complexes that may be 
even more toxic than the unrepaired single-strand breaks 
which result from PARP inhibition. This concept was termed 
“PARP trapping” by Murai et al14 and its characterization 
impacted PARP inhibitor development in two important 
ways. First, this work showed that pathways other than HR 
may be essential for repairing the PARP–DNA complexes, 
therefore providing rationale for treating tumors with defects 
in the FEN1, polymerase β, postreplication repair, and 
Fanconi anemia pathways. Secondly, these investigators 
???
??
?
??
?
Figure 1 Chemical structure of veliparib.
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demonstrated a difference between PARP inhibitors in the 
ability to trap PARP, despite similarities in the ability to 
inhibit PARP catalytic activity. In this regard, veliparib was 
inferior to both niraparib and olaparib in trapping PARP. 
This finding may be related to the period of time that PARP 
is “trapped” onto the DNA, and it could have implications 
for dosing and toxicity of the various agents.15
Preclinical activity
Donawho et al3 produced one of the earliest and most com-
plete assessments of the preclinical activity of veliparib, 
and showed that veliparib potentiated the activity of temo-
zolomide, cisplatin, carboplatin, and cyclophosphamide in a 
variety of tumors, including melanoma, glioma, lymphoma, 
colon carcinoma, and breast carcinoma. They also demon-
strated that veliparib crosses the blood–brain barrier, provid-
ing further rationale for its pairing with temozolomide to 
treat intracranial tumors. Further, veliparib also potentiated 
the effect of fractionated radiation through its impairment of 
both single- and double-strand break repair pathways.
Additional studies have built on these earlier preclinical 
observations. Palma et al16 expanded the scope of tumors and 
showed combinatorial activity of veliparib and temozolomide 
in multiple types of lung cancer as well as in pancreatic and 
prostate cancer xenografts. Interestingly, activity was demon-
strated in models that had acquired resistance to single-agent 
temozolomide, and conventional measures of temozolomide 
resistance such as expression of methylguanine methyl-
transferase (MGMT) or mismatch repair proteins did not 
correlate with the degree of sensitivity to the combination 
of temozolomide + veliparib. Additional work by Palma 
et al16 showed that potentiation of temozolomide toxicity 
was dose-dependent and that extended veliparib scheduling 
was not more beneficial than limiting administration to be 
simultaneous with 5-day courses of temozolomide.17
Lin et al11 further explored genetic predictors of veliparib 
in glioblastoma models, demonstrating that veliparib activity 
may be greatest in cells with PTEN deficiency, which charac-
terizes up to one-third of gliomas. They also demonstrated the 
importance of using doses in laboratory experiments that are 
clinically relevant and can achieve serum concentrations that 
are feasible in humans, which is a key point also emphasized 
by other investigators.18
As mentioned above, PARP inhibitors appear to work in 
different ways, including interfering with the repair of DNA 
breaks as well as by stabilizing the PARP–DNA complex 
and inducing cytotoxicity through PARP trapping. In a recent 
article, Murai et al19 reported that synergy with conventional 
cytotoxic agents can be affected by which mechanism of 
action is greatest for a particular inhibitor. For example, while 
olaparib and veliparib have similar inhibitory effects on PARP 
catalytic activity, the degree of PARP trapping is greater with 
olaparib. This mechanism appears to be particularly important 
when a PARP inhibitor is combined with temozolomide, 
as the combination of olaparib + temozolomide has greater 
in vitro activity than that of veliparib + temozolomide. How-
ever, both inhibitors showed robust synergy in combination 
with camptothecin, suggesting that activity with that particular 
combination may be mediated more by downregulating direct 
PARP catalytic activity.
Several studies have also reported the radiosensitizing 
effect of veliparib in a variety of solid tumors,20–23 including 
under the hypoxic conditions often found in larger tumors.24 
In cultured glioblastoma cells, veliparib enhanced the lethal-
ity of radiation, especially in combination with temozolo-
mide. Interestingly, this effect again was seen irrespective of 
the MGMT status of the tumor cells.25 Similar combinatorial 
efficacy has also been seen with veliparib and radiation 
combined with oxaliplatin, 5-fluorouracil, or irinotecan in 
cultured colorectal carcinoma cells.26
There have been a limited number of direct preclinical 
comparisons between PARP inhibitors. In addition to the 
studies reported above, Shen et al27 reported that the newer-
generation PARP inhibitor BMN 673 exhibited selective 
cytotoxicity and elicited DNA repair biomarkers at much 
lower concentrations than olaparib or veliparib. A further 
study suggests that PARP inhibitors may vary in their “off-
target” effects, and this may significantly impact their effi-
cacy against certain tumor types. For example, Jelinic and 
Levine28 showed that olaparib reduced DNA damage repair 
activity via G
2
 cell cycle arrest in a p53-dependent manner, 
an effect not seen with veliparib.
In summary, the preclinical studies provide rationale for 
various clinical applications, including the targeting of specific 
tumor types and possible therapeutic combinations. These 
studies also provide some insight into possible mechanisms of 
action and the relative efficacy of different agents, but are ulti-
mately limited somewhat by the artificial nature of the preclini-
cal models used. Only through rigorous clinical trials will the 
ultimate utility, or futility, of a particular agent be decided.
Clinical trials
Veliparib has already been studied in a variety of Phase I and 
II trials, and currently there are five Phase III trials ongoing. 
Results from several reported studies are summarized in 
Table 1. To date, there have been no head-to-head clinical 
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studies of different PARP inhibitors, which therefore limits 
the assessment of how veliparib compares to the six other 
agents currently in clinical trials.
Dose-finding and toxicity of single-agent 
trials of veliparib
Puhalla et al29 have reported in abstract form the Phase I 
trial of veliparib in adults with relapsed cancers, with doses 
ranging from 50 to 500 mg bid being studied. They defined 
the recommended Phase II dose (RP2D) of single-agent veli-
parib as 400 mg bid. Given that veliparib has been studied 
using tablet strengths of 10 and 40 mg, patients receiving the 
RP2D dose will take up to 20 tablets bid, which compares 
to 16 tablets bid of olaparib at its RP2D. The toxicity of this 
dose is best estimated from a Phase II trial in 50 patients with 
ovarian cancer conducted by Coleman et al.30 In that study, 
the most common side effects were gastrointestinal, with half 
of the patients having nausea of at least grade 2 (46%) or 
grade 3 (4%) severity. An additional 18% of these patients 
had grade 2 vomiting. In general, gastrointestinal toxicity was 
seen primarily in the earlier courses, and was manageable 
with aggressive antiemetics, delays, and dose reductions. 
Fatigue was seen in one-third of patients, but was generally 
grade 2. Myelosuppression was modest, with only 2% hav-
ing either grade 3–4 neutropenia or thrombocytopenia. The 
median dose intensity was 78%. The overall toxicity profile 
seen with veliparib is somewhat similar to that reported in 
Phase II trials of other PARP inhibitors such as olaparib. For 
example, in a recent trial of 46 women with ovarian cancer 
treated with single-agent olaparib, grade 3 fatigue was seen 
in 11% of patients.31 While three-fourths of patients experi-
enced nausea, only 26% of patients had grade 2 nausea, and 
grade 3 nausea was not reported. Serious late effects such 
as secondary leukemia and myelodysplastic syndrome have 
occasionally been observed following treatment with PARP 
inhibitors,32 although the extensive pretreatment of patients 
included in these studies makes attribution of this compli-
cation very difficult. However, given that double-strand 
breaks may build up in normal tissues following treatment 
with PARP inhibitors over time,33 continued surveillance for 
second malignancies is reasonable.
Combination trials using veliparib and cytotoxic chemo-
therapy have used either the full RP2D as above, or lower 
dosing, depending in part on the expected toxicity related to 
the conventional agent. This has led to a wide range of doses 
being studied, as noted in Table 1. In general, no unusual 
Table 1 Key published clinical trials with veliparib for treatment of solid tumors
Study N Phase Other agents Population Veliparib dose Comments
Puhalla 
et al29
88 1 – BRCA-mutated, 
platinum-refractory 
ovarian or basal-like 
breast cancer
RP2D was  
400 mg bid
For 28 patients with mutant BRCA treated 
at RP2D, overall response rate was 40%, 
with clinical benefit rate of 68%
Coleman 
et al30
50 ii – Ovarian with 
BRCA1/2 mutation
400 mg bid 26% response rate, well tolerated
Rugo 
et al34
71 ii Carboplatin,
paclitaxel
Triple-negative 
breast cancer
150 mg bid Higher rate of pathologic complete response 
(2% vs 26%) with veliparib
Somlo 
et al35
41 ii Veliparib followed 
by veliparib +
carboplatin
BRCA-mutated 
breast cancer
400 mg bid (single 
agent); 150 mg bid 
(with carboplatin)
encouraging activity seen to single-agent 
veliparib
Kummar 
et al36
37/38 Randomized
ii
With/without oral 
cyclophosphamide
Ovarian cancer 60 mg qd Addition of veliparib did not improve activity
Kunos 
et al41
27 I/ll Topotecan, 
growth factor
Recurrent uterine 
cervix cancer
10 mg bid days 
1–5
Minimal activity seen with veliparib dose 
10 mg bid
Kummar 
et al37
24 1 Topotecan Refractory solid 
tumors and 
lymphoma
10 mg bid Increases in yH2AX in circulating tumor cells 
shows PARP inhibition can modulate the 
capacity to repair DNA damage
Su et al38 29 1 Temozolomide Pediatric brain 
tumor
25 mg/m2 bid Similar pharmacokinetics in children
Hussain 
et al39
25 Pilot Temozolomide Prostate cancer 40 mg bid days 
1–7
Well tolerated but only modestly active
Reiss 
et al44
22 1 Whole abdomen 
irradiation
Peritoneal
carcinomatosis
40–160 mg bid well tolerated, with some prolonged disease 
stability
Mehta 
et al45
81 1 Whole brain 
irradiation
Brain
metastases
10–300 mg bid 
(RP2D was 
200 mg bid)
Well tolerated, with improved efficacy 
compared to predicted results from 
established nomogram
Abbreviations: RP2D, recommended Phase II dose; bid, twice-daily; qd, once-daily; PARP, poly(ADP-ribose) polymerase.
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toxicities have been encountered in these trials to date, 
although myelosuppression may be enhanced when veliparib 
is combined with a drug known to cause this effect.
Activity of veliparib in clinical trials
The single-agent Phase I trial conducted by Puhalla et al29 
involved 88 patients, and was designed to enrich the popula-
tion with patients more likely to respond to PARP inhibitors. 
Eligibility criteria included patients with BRCA-mutated 
tumors as well as those with BRCA-like tumors, such as 
serous ovarian cancer and basal-like breast cancer. At the 
RP2D, 28 BRCA-mutated patients were evaluable, and the 
response rate and clinical benefit rate (complete + partial 
responses + stable disease) were 40% and 68%, respectively. 
This compares to 4% and 38%, respectively, of patients with 
tumors wild-type for BRCA.
Coleman et al30 then performed a Phase II study using 
the same dose of 400 mg veliparib bid in patients with 
BRCA-mutated ovarian cancer. Of the 50 evaluable patients, 
30 (60%) were platinum resistant. The study was designed 
to identify with 90% power a response rate of 25%. For all 
patients, the response rate was 26%, thus meeting the pre-
defined definition of activity in this multicenter prospective 
study. For platinum-resistant and platinum-sensitive patients, 
the response rate was 20% and 35%, respectively, (P=0.33).
Another encouraging Phase II result came from the 
I-SPY 2 trial for patients with triple-negative breast cancer.34 
Patients in the experimental group received veliparib plus 
carboplatin and paclitaxel, while the control group was 
assigned to standard paclitaxel followed by anthracycline 
chemotherapy. Women in the veliparib group were twice 
as likely to have a pathologic complete response com-
pared to those receiving standard therapy (52% vs 26%). 
Researchers then used this data to calculate a 92% Bayesian 
predictive probability that the veliparib regimen would be 
statistically superior to standard therapy alone for women 
with triple-negative disease in a Phase III trial enrolling 
300 patients.
Additional studies combining veliparib with conventional 
chemotherapy agents have also been reported. A multicenter 
Phase II study recently reported in abstract form by Somlo et al35 
involved patients with metastatic BRCA-mutated breast 
cancer. Patients received veliparib 400 mg bid daily until 
progression, at which time carboplatin was added and the 
veliparib dose reduced to 150 mg bid. A partial response rate 
of 20% was seen in patients receiving four cycles of single-
agent veliparib, and larger trials of veliparib are planned both 
alone and in combination with chemotherapy.
Unfortunately, compelling clinical activity has not been 
demonstrated in all trials to date. In a randomized Phase II 
trial conducted by Kummar et al36 ovarian cancer patients 
received the combination of veliparib 60 mg once daily 
together with daily oral cyclophosphamide, which had pre-
viously been established as the RP2D based on an earlier 
Phase I trial of this combination.37 Control patients received 
cyclophosphamide alone. While the combination was well 
tolerated, there was no improvement seen from the addition 
of this dose of veliparib to metronomic administration of 
cyclophosphamide.
The combination of veliparib and temozolomide has been 
described, although many reports are preliminary. Myelo-
toxicity can be considerable with this combination, and so 
the dose of veliparib is often as low as one-tenth of the usual 
single-agent dose. Veliparib doses of 40 mg bid (and an 
equivalent dose of 25 mg/m2 in a pediatric trial) together with 
temozolomide 150 mg/m2/day for 5 days appear tolerable and 
are associated with some extent of disease stabilization in 
glioma38 and prostate cancer,39 although minimal activity was 
observed for those with refractory hepatocellular carcinoma.40 
Other combinations with topotecan have been reported41,42 
and continue to be under investigation (Table 2).
In regard to combination studies, a recent preclinical 
assessment of PARP inhibitors combined with temozolo-
mide and irinotecan to treat an orthotopic mouse model 
of Ewing sarcoma may possibly inform further decisions 
about dosing and combination with chemotherapy agents.15 
PARP inhibitors are an attractive option for the treatment of 
Ewing sarcoma because the characteristic EWS–FLI1 fusion 
protein that drives tumor growth interacts with PARP-1 
through a proposed positive feedback loop,43 which may 
make Ewing sarcoma cells particularly sensitive to PARP 
inhibitors in vitro. Although limited single-agent activity in 
the orthotopic model was seen from any of the three agents 
tested (olaparib, BMN-673, or veliparib), there was synergy 
with the combined use of PARP inhibitors + temozolomide, 
and especially with the further addition of irinotecan.15 
Interestingly, veliparib was the least active of the three 
PARP inhibitors at the dosages used, although later testing 
of veliparib at higher doses demonstrated both tolerability 
as well as similar efficacy to both olaparib and BMN-673. 
Although the previous clinical studies mentioned above had 
tried to maximize the temozolomide dose while escalating 
veliparib dose,38–40 the Ewing sarcoma data would suggest 
that the opposite should be done, at least for that tumor type. 
It is not clear whether this strategy should be employed when 
treating other cancers, although these interesting results do 
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raise questions when combinatorial therapies fail to produce 
the desired level of activity.
Finally, some early trials have investigated the combina-
tion of veliparib and therapeutic irradiation. In the Phase I 
setting, veliparib was studied with whole abdominal radia-
tion in patients with peritoneal carcinomatosis.44 The highest 
studied dose of veliparib (160 mg bid) was well tolerated, 
with some suggestion of disease stability seen. When given in 
combination with whole-brain radiotherapy for patients with 
metastatic cancer, Mehta et al45 reported the dose of 200 mg 
bid as the RP2D.
Ongoing clinical trials
As seen in Table 2, clinicaltrials.gov lists at least 19 Phase 
II or III trials using veliparib, currently recruiting patients. 
These studies include such cancers as breast, prostate, head 
and neck, lung, pancreatic, ovarian, colorectal, and glioma. 
While many of these studies couple veliparib with conven-
tional cytotoxic chemotherapy, some involve combination 
with radiation or other targeted agents such as lapatinib. 
The five open Phase III trials are focused on lung cancer, 
breast cancer, and glioblastoma. In addition to these, there 
are multiple Phase I trials studying an even broader array of 
combinations and tumor types.
Mechanisms of resistance
Although exciting activity has been seen with the use of 
PARP inhibitors in treating BRCA-deficient tumors, some 
patients still do not respond initially or develop acquired 
resistance with continued treatment. There are likely several 
potential mechanisms that may explain resistance in these 
patients. First, there may be secondary genetic and/or epige-
netic events that restore functional HR in tumors that were 
once HR deficient.46 Secondary mutations that restore BRCA 
protein function and lead to cisplatin resistance have been 
reported in patients with recurrent ovarian cancer,47 and such 
secondary mutations have been seen in patients who initially 
respond but then develop resistance to olaparib.48
Other potential mechanisms of resistance include 
somatic mutations of the p53 binding protein TP53BP1,49 
which can result in partial restoration in HR. Drug efflux 
through transporters such as the multidrug resistance protein 
1 (P-glycoprotein) has also been implicated in resistance, 
with some suggestion that cotreatment with medications to 
Table 2 Key ongoing clinical Phase II or III trials of veliparib in patients with solid tumors
Clinicaltrials.gov
identifier
Phase Other agents Population
Phase iii
NCT02163694 III (randomized) Carboplatin, paclitaxel HER2-negative metastatic/unresectable 
BRCA-mutated breast cancer
NCT02106546 III (randomized) Carboplatin, paclitaxel Untreated advanced/metastatic lung cancer
NCT02264990 III (randomized) Carboplatin, paclitaxel First cytotoxic chemotherapy for metastatic/
advanced non-small-cell lung cancer
NCT02032277 III (randomized) Carboplatin, other standard 
chemotherapy
Early-stage triple-negative breast cancer
NCT02152982 ll/lll (randomized) Temozolomide Newly diagnosed glioblastoma
Phase ii
NCT02158507 ii Lapatinib Metastatic triple-negative breast cancer
NCT01585805 II (randomized) Gemcitabine, cisplatin Advanced/metastatic pancreatic cancer
NCT01576172 II (randomized) Abiraterone/prednisone Metastatic hormone-resistant prostate cancer
NCT01638546 II (randomized) Temozolomide Relapsed small-cell lung cancer
NCT01506609 ii Temozolomide, or carboplatin/paclitaxel BRCA-mutated metastatic breast cancer
NCT01827384 ii Monotherapy based on genetic testing 
(NCI-MPACT study)
Advanced solid tumors
Phase I/ll
NCT01514201 I/ll Temozolomide, radiation Children with newly diagnosed pontine glioma
NCT01711541 I/ll Combination chemotherapy Stage IV head and neck cancer
NCT01351909 I/ll (randomized) Cyclophosphamide Advanced/metastatic breast cancer
NCT01642251 I/ll (randomized) Cisplatin, etoposide Advanced or metastatic lung cancer
NCT01690598 I/ll Topotecan Relapsed ovarian cancer with negative  
or unknown BRCA status
NCT01489865 I/ll Fluorouracil, oxaliplatin Metastatic pancreatic cancer
NCT01472783 I/ll – Relapsed ovarian cancer with BRCA mutation
Abbreviation: NCI-MPACT, National Cancer Institute-Molecular Profiling based Assignment of Cancer Therapeutics.
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block P-glycoprotein can help reverse resistance to PARP 
inhibitors.50 Finally, loss or even reduction of PARP1 expres-
sion may also be associated with acquired resistance.51 Fur-
ther prospective studies of all of these potential mechanisms 
may ultimately help identify which patients are most likely 
to benefit from PARP inhibition. It is unclear at this point 
whether there are specific mechanisms of resistance that dif-
fer between individual PARP inhibitors, and no mechanism 
to date appears necessarily unique to veliparib.
Potential biomarkers
As discussed above, the hallmark of sensitivity to PARP 
inhibition is deficient DNA repair. The most compelling clini-
cal benefit to date in single-agent studies has been in trials 
selecting for patients whose tumors have either confirmed or 
suspected HR deficiencies, such as BRCA mutations, patients 
with BRCA-like tumors such as basal- or triple-negative breast 
cancer, or patients who are platinum sensitive. However, it is 
clear that a subset of ovarian and breast cancer patients who 
lack BRCA mutations can respond to PARP inhibitors, and 
so there is no absolute correlation between these predictors 
and clinical response.29,52 Other specific genes involved in 
the DNA damage response, such as HPIβ, have also been 
reported as putative biomarkers of sensitivity to veliparib, 
either given alone or in combination with chemotherapy.53 
Given the complexity of the DNA repair process and the 
complicating factor of tumor heterogeneity, the search for 
genetic biomarkers to predict sensitivity to PARP inhibitors 
remains quite complicated, such that single biomarker models 
may not ultimately prove beneficial.54
PARP expression level and/or PARP activity in tumor 
tissue may also play a role in determining the sensitivity to 
PARP inhibitors,51 and they are being prospectively studied 
in clinical trials. Elevated levels of PAR-related proteins 
as assessed by Western blotting or immunohistochemistry 
have also been shown to predict sensitivity of human cancer 
cells to PARP inhibitors55 and could be another avenue of 
investigation in clinical trials.
In acute myeloid leukemia cells, BRCA1 protein levels 
inversely correlate with PARP inhibitory activity, with the 
majority of cell lines having low BRCA1 levels, presumably 
due to posttranscriptional regulatory mechanisms.56 This 
raises the possibility that immunostaining of tumors for 
BRCA1 could potentially be a useful biomarker, although 
this approach has not yet been reported in a clinical trial. One 
biomarker combination predicted to be exquisitely sensitive 
to PARP inhibitors is high 53BP1 expression coupled with 
methylation of BRCA1, although these findings were only 
noted in a small subset of patients with triple-negative breast 
cancers.57 It is hoped that further molecular characterization 
of tumors using genetic profiling techniques will identify 
biomarkers that can be validated in clinical trials, and this 
remains a focus of continued research.
Conclusions and challenges ahead
PARP inhibitors represent an exciting demonstration of 
the potential for targeted therapy and genetic selection of 
patients. The recent FDA approval of olaparib, and the 
encouraging data from clinical trials of related compounds 
such as veliparib, suggests the worthiness of pursuing this 
therapeutic strategy. Many questions remain regarding the 
use of these agents, including their proper sequence in 
treatment. For example, in ovarian cancer, there is debate 
about whether these targeted agents should be used before 
or after platinum chemotherapy, in combination with 
conventional cytotoxic agents, or as maintenance therapy 
for high-risk, genetically susceptible patients following 
standard treatment.58 These issues will be better clarified 
in the multiple Phase II and III trials, which are already 
underway.
Although the PARP inhibitors now in clinical trials 
have shown some preclinical differences, especially in the 
degree of PARP trapping, the true clinical significance of 
these differences is not yet clear. There have been no head-
to-head clinical trials of different agents in the same class, 
and comparisons between trials are complicated. As noted 
above, some preclinical studies suggest that veliparib is not 
the most robust PARP inhibitor in its class, and in fact there 
is now a clinical trial of BMN-673 open for patients with 
BRCA1/2-mutated ovarian cancer who have failed other 
PARP inhibitors (clinicaltrials.gov identifier NCT02326844). 
Nevertheless, the activity and tolerability of veliparib seen 
in early phase studies is exciting, and the likelihood of FDA 
approval will hinge on the results of the ongoing Phase III 
trials. Whether more than one targeted agent in a class will 
receive licensure, as occurred with the EGFR inhibitors 
erlotinib and gefitinib, remains to be seen.
Substantial challenges lie ahead for the further devel-
opment of veliparib. For the translational scientist, the 
identification of reliable biomarkers will be critical for the 
success of this targeted agent. For the clinical scientist, 
opportunities exist for expanding veliparib treatment for 
tumors beyond those already studied, including for Ewing 
sarcoma,15 lymphoma,42 and even leukemia.59 Finally, 
thoughtful trial design regarding the dosing and sequence 
of veliparib and its combination with radiation or other 
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chemotherapy agents will be necessary to realize the full 
potential of this drug.
Disclosure
The author reports no conflicts of interest in this work.
References
 1. Basu B, Sandhu SK, de Bono JS. PARP inhibitors: mechanism of action 
and their potential role in the prevention and treatment of cancer. Drugs. 
2012;72(12):1579–1590.
 2. Olaparib approved for advanced ovarian cancer. Cancer Discov. 
2015;5(3):218.
 3. Donawho CK, Luo Y, Luo Y, et al. ABT-888, an orally active poly(ADP-
ribose) polymerase inhibitor that potentiates DNA-damaging agents in 
preclinical tumor models. Clin Cancer Res. 2007;13(9):2728–2737.
 4. Kummar S, Kinders R, Gutierrez ME, et al. Phase 0 clinical trial of 
the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with 
advanced malignancies. J Clin Oncol. 2009;27(16):2705–2711.
 5. Salem AH, Giranda VL, Mostafa NM. Population pharmacokinetic 
modeling of veliparib (ABT-888) in patients with non-hematologic 
malignancies. Clin Pharmacokinet. 2014;53(5):479–488.
 6. Li X, Delzer J, Voorman R, de Morais SM, Lao Y. Disposition and 
drug-drug interaction potential of veliparib (ABT-888), a novel and 
potent inhibitor of poly(ADP-ribose) polymerase. Drug Metab Dispos. 
2011;39(7):1161–1169.
 7. Penning TD, Zhu GD, Gandhi VB, et al. Discovery of the Poly(ADP-
ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-
yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of 
cancer. J Med Chem. 2009;52(2):514–523.
 8. Li J, Kim S, Sha X, Wiegand R, Wu J, LoRusso P. Complex disease-, 
gene-, and drug-drug interactions: impacts of renal function, CYP2D6 
phenotype, and OCT2 activity on veliparib pharmacokinetics. Clin 
Cancer Res. 2014;20(15):3931–3944.
 9. Kikuchi R, Lao Y, Bow DA, et al. Prediction of clinical drug-drug inter-
actions of veliparib (ABT-888) with human renal transporters (OAT1, 
OAT3, OCT2, MATE1, and MATE2K). J Pharm Sci. 2013;102(12): 
4426–4432.
 10. McCabe N, Turner NC, Lord CJ, et al. Deficiency in the repair of DNA 
damage by homologous recombination and sensitivity to poly(ADP-
ribose) polymerase inhibition. Cancer Res. 2006;66(16):8109–8115.
 11. Lin F, de Gooijer MC, Roig EM, et al. ABCB1, ABCG2, and PTEN 
determine the response of glioblastoma to temozolomide and ABT-888 
therapy. Clin Cancer Res. 2014;20(10):2703–2713.
 12. Duan W, Gao L, Aguila B, Kalvala A, Otterson GA, Villalona-Calero MA. 
Fanconi anemia repair pathway dysfunction, a potential therapeutic 
target in lung cancer. Front Oncol. 2014;4:368.
 13. Shall S, de Murcia G. Poly(ADP-ribose) polymerase-1: what have 
we learned from the deficient mouse model? Mutat Res. 2000;460(1): 
1–15.
 14. Murai J, Huang SY, Das BB, et al. Trapping of PARP1 and PARP2 by 
clinical PARP inhibitors. Cancer Res. 2012;72(21):5588–5599.
 15. Stewart E, Goshorn R, Bradley C, et al. Targeting the DNA repair 
pathway in Ewing sarcoma. Cell Rep. 2014;9(3):829–841.
 16. Palma JP, Wang YC, Rodriguez LE, et al. ABT-888 confers broad 
in vivo activity in combination with temozolomide in diverse tumors. 
Clin Cancer Res. 2009;15(23):7277–7290.
 17. Palma JP, Rodriguez LE, Bontcheva-Diaz VD, et al. The PARP inhibi-
tor, ABT-888 potentiates temozolomide: correlation with drug levels 
and reduction in PARP activity in vivo. Anticancer Res. 2008;28(5A): 
2625–2635.
 18. Gupta SK, Mladek AC, Carlson BL, et al. Discordant in vitro and 
in vivo chemopotentiating effects of the PARP inhibitor veliparib in 
temozolomide-sensitive versus -resistant glioblastoma multiforme 
xenografts. Clin Cancer Res. 2014;20(14):3730–3741.
 19. Murai J, Zhang Y, Morris J, et al. Rationale for poly(ADP-ribose) poly-
merase (PARP) inhibitors in combination therapy with camptothecins 
or temozolomide based on PARP trapping versus catalytic inhibition. 
J Pharmacol Exp Ther. 2014;349(3):408–416.
 20. Schaefer NG, James E, Wahl RL. Poly(ADP-ribose) polymerase inhibi-
tors combined with external beam and radioimmunotherapy to treat 
aggressive lymphoma. Nucl Med Commun. 2011;32(11):1046–1051.
 21. Nowsheen S, Bonner JA, Yang ES. The poly(ADP-ribose) polymerase 
inhibitor ABT-888 reduces radiation-induced nuclear EGFR and aug-
ments head and neck tumor response to radiotherapy. Radiother Oncol. 
2011;99(3):331–338.
 22. Efimova EV, Mauceri HJ, Golden DW, et al. Poly(ADP-ribose) poly-
merase inhibitor induces accelerated senescence in irradiated breast 
cancer cells and tumors. Cancer Res. 2010;70(15):6277–6282.
 23. Albert JM, Cao C, Kim KW, et al. Inhibition of poly(ADP-ribose) 
polymerase enhances cell death and improves tumor growth delay 
in irradiated lung cancer models. Clin Cancer Res. 2007;13(10): 
3033–3042.
 24. Liu SK, Coackley C, Krause M, Jalali F, Chan N, Bristow RG. A 
novel poly(ADP-ribose) polymerase inhibitor, ABT-888, radiosen-
sitizes malignant human cell lines under hypoxia. Radiother Oncol. 
2008;88(2):258–268.
 25. Barazzuol L, Jena R, Burnet NG, et al. Evaluation of poly (ADP-ribose) 
polymerase inhibitor ABT-888 combined with radiotherapy and temo-
zolomide in glioblastoma. Radiat Oncol. 2013;8:65.
 26. Shelton JW, Waxweiler TV, Landry J, et al. In vitro and in vivo 
enhancement of chemoradiation using the oral PARP inhibitor ABT-888 
in colorectal cancer cells. Int J Radiat Oncol Biol Phys. 2013;86(3): 
469–476.
 27. Shen Y, Rehman FL, Feng Y, et al. BMN 673, a novel and highly potent 
PARP1/2 inhibitor for the treatment of human cancers with DNA repair 
deficiency. Clin Cancer Res. 2013;19(18):5003–5015.
 28. Jelinic P, Levine DA. New insights into PARP inhibitors’ effect on cell 
cycle and homology-directed DNA damage repair. Mol Cancer Ther. 
2014;13(6):1645–1654.
 29. Puhalla S, Beumer JH, Pahuja S, et al. Final results of a phase 1 syudy of 
single-agent veliparib in patient swith either BRCA1/2-mutated cancer, 
platinum-refractory ovarian, or basal-like breast cancer [Abstract 2570]. 
J Clin Oncol. 2014;32:5s.
 30. Coleman RL, Sill MW, Bell-McGuinn K, et al. A phase II evaluation 
of the potent, highly selective PARP inhibitor veliparib in the treatment 
of persistent or recurrent epithelial ovarian, fallopian tube, or primary 
peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 
mutation – An NRG Oncology/Gynecologic Oncology Group study. 
Gynecol Oncol. Epub 2015 Mar 24.
 31. Liu JF, Barry WT, Birrer M, et al. Combination cediranib and 
olaparib versus olaparib alone for women with recurrent platinum-
sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol. 
2014;15(11):1207–1214.
 32. Kaufman B, Shapira-Frommer R, Schmutzler RK, et al. Olaparib 
monotherapy in patients with advanced cancer and a germline BRCA1/2 
mutation. J Clin Oncol. 2015;33(3):244–250.
 33. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) 
polymerase in tumors from BRCA mutation carriers. N Engl J Med. 
2009;361(2):123–134.
 34. Rugo HS, Olopade O, DeMichele A, et al. Veliparib/carboplatin plus 
standard neoadjuvant therapy for high-risk breast cancer: first efficacy 
results from the I-SPY 2 trial. Cancer Res. 2013;73(24 Suppl):Abstract 
S5-02.
 35. Somlo G, Frankel PH, Luu TH, et al. Phase II trial of single-agent PARP 
inhibitor ABT-888 (veliparib) followed by post-progression therapy of 
veliparib with carboplatin in patients with BRCA-associated metastatic 
breast cancer [Abstract 1021]. J Clin Oncol. 2014;32:5s.
 36. Kummar S, Oza AM, Fleming GF, et al. Randomized trial of oral 
cyclophosphamide and veliparib in high-grade serous ovarian, primary 
peritoneal, or fallopian tube cancers, or BRCA-mutant ovarian cancer. 
Clin Cancer Res. 2015;21(7):1574–1582.
OncoTargets and Therapy
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/oncotargets-and-therapy-journal
OncoTargets and Therapy is an international, peer-reviewed, open 
access journal focusing on the pathological basis of all cancers, potential 
targets for therapy and treatment protocols employed to improve the 
management of cancer patients. The journal also focuses on the impact 
of management programs and new therapeutic agents and protocols on 
patient perspectives such as quality of life, adherence and satisfaction. 
The manuscript management system is completely online and includes 
a very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
OncoTargets and Therapy 2015:8 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
1939
Veliparib for solid tumors
 37. Kummar S, Ji J, Morgan R, et al. A phase I study of veliparib in combina-
tion with metronomic cyclophosphamide in adults with refractory solid 
tumors and lymphomas. Clin Cancer Res. 2012;18(6):1726–1734.
 38. Su JM, Thompson P, Adesina A, et al. A phase I trial of veliparib 
(ABT-888) and temozolomide in children with recurrent CNS tumors: 
a pediatric brain tumor consortium report. Neuro Oncol. 2014;16(12): 
1661–1668.
 39. Hussain M, Carducci MA, Slovin S, et al. Targeting DNA repair with 
combination veliparib (ABT-888) and temozolomide in patients with 
metastatic castration-resistant prostate cancer. Invest New Drugs. 2014; 
32(5):904–912.
 40. He AR, Tesfaye A, Smith D, et al. Phase II trial of temozolomide and 
veliparib combination therapy for sorafenib-refractory advanced hepa-
tocellular carcinoma [Abstract 240]. J Clin Oncol. 2014;32(3 Suppl).
 41. Kunos C, Deng W, Dawson D, et al. A phase I-II evaluation of veliparib 
(NSC #737664), topotecan, and filgrastim or pegfilgrastim in the treat-
ment of persistent or recurrent carcinoma of the uterine cervix: an NRG 
Oncology/Gynecologic Oncology Group study. Int J Gynecol Cancer. 
2015;25(3):484–492.
 42. Kummar S, Chen A, Ji J, et al. Phase I study of PARP inhibitor ABT-888 
in combination with topotecan in adults with refractory solid tumors 
and lymphomas. Cancer Res. 2011;71(17):5626–5634.
 43. Brenner JC, Feng FY, Han S, et al. PARP-1 inhibition as a targeted strat-
egy to treat Ewing’s sarcoma. Cancer Res. 2012;72(7):1608–1613.
 44. Reiss KA, Herman JM, Zahurak M, et al. A phase I study of veliparib 
(ABT-888) in combination with low-dose fractionated whole abdominal 
radiation therapy in patients with advanced solid malignancies and 
peritoneal carcinomatosis. Clin Cancer Res. 2015;21(1):68–76.
 45. Mehta MP, Wang D, Wang F, et al. Veliparib in combination with 
whole brain radiation therapy in patients with brain metastases: results 
of a phase 1 study. J Neurooncol. 2015;122(2):409–417.
 46. Edwards SL, Brough R, Lord CJ, et al. Resistance to therapy caused by 
intragenic deletion in BRCA2. Nature. 2008;451(7182):1111–1115.
 47. Norquist B, Wurz KA, Pennil CC, et al. Secondary somatic mutations 
restoring BRCA1/2 predict chemotherapy resistance in hereditary 
ovarian carcinomas. J Clin Oncol. 2011;29(22):3008–3015.
 48. Barber LJ, Sandhu S, Chen L, et al. Secondary mutations in BRCA2 
associated with clinical resistance to a PARP inhibitor. J Pathol. 2013; 
229(3):422–429.
 49. Jaspers JE, Kersbergen A, Boon U, et al. Loss of 53BP1 causes PARP 
inhibitor resistance in Brca1-mutated mouse mammary tumors. Cancer 
Discov. 2013;3(1):68–81.
 50. Rottenberg S, Jaspers JE, Kersbergen A, et al. High sensitivity of 
BRCA1-deificent mammary tumors to the PARP inhibitor AZD2281 
alone and in combination with platinum drugs. Proc Natl Acad Sci 
U S A. 2008;105(44):17079–17084.
 51. Pettitt SJ, Rehman FL, Bajrami I, et al. A genetic screen using the 
PiggyBac transposon in haploid cells identifies Parp1 as a mediator of 
olaparib toxicity. PLoS One. 2013;8(4):e61520.
 52. Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with 
recurrent high-grade serous or poorly differentiated ovarian carcinoma 
or triple-negative breast cancer: a phase 2, multicentre, open-label, 
non-randomised study. Lancet Oncol. 2011;12(9):852–861.
 53. Lee YH, Liu X, Qiu F, O’Connor TR, Yen Y, Ann DK. HP1β is a 
biomarker for breast cancer prognosis and PARP inhibitor therapy. 
PLoS One. 2015;10(3):e0121207.
 54. Wang X, Weaver DT. The ups and downs of DNA repair biomarkers 
for PARP inhibitor therapies. Am J Cancer Res. 2011;1(3):301–327.
 55. Michels J, Vitale I, Galluzzi L, et al. Cisplatin resistance associated 
with PARP hyperactivation. Cancer Res. 2013;73(7):2271–2280.
 56. Faraoni I, Compagnone M, Lavorgna S, et al. BRCA1, PARP1 and 
γH2AX in acute myeloid leukemia: role as biomarkers of response 
to the PARP inhibitor olaparib. Biochim Biophys Acta. 2015;1852(3): 
462–472.
 57. Jacot W, Thezenas S, Senal R, et al. BRCA1 promoter hypermethyla-
tion, 53BP1 protein expression and PARP-1 activity as biomarkers of 
DNA repair deficit in breast cancer. BMC Cancer. 2013;13:523.
 58. Liu JF, Konstantinopoulos PA, Matulonis UA. PARP inhibitors in 
ovarian cancer: current status and future promise. Gynecol Oncol. 2014; 
133(2):362–369.
 59. Horton TM, Jenkins G, Pati D, et al. Poly(ADP-ribose) polymerase 
inhibitor ABT-888 potentiates the cytotoxic activity of temozo-
lomide in leukemia cells: influence of mismatch repair status and 
O6-methylguanine-DNA methyltransferase activity. Mol Cancer Ther. 
2009;8(8):2232–2242.
